Companies like "Prescriberee" operate with a business model targeting life sciences firms as clients. Their goal is not holistic care but efficiently converting interested patients into prescriptions, with one executive citing a 90% conversion rate for eligible patients.
Pharma companies now partner with telehealth providers to offer coupons that reduce the cost of the physician consultation itself. This marketing tactic incentivizes patients to seek a prescription for a specific drug, raising questions about overprescribing and conflicts of interest.
During the 2022-2025 biotech financing "chill," venture capitalists were so focused on de-risking and protecting their existing portfolios that they wouldn't engage in deep due diligence for preclinical companies like Colonia, regardless of their potential.
Medicare's temporary "Bridge" program funds weight loss drugs for seniors, but its eventual end will likely cause patients to regain weight. This negates the health benefits, potentially wasting the tens of billions of dollars spent on temporary coverage.
After struggling to raise funds for years, Colonia Therapeutics' presentation of positive data in just four patients at the ASH conference was the catalyst for acquisition talks. It shows that a single, compelling data reveal at an industry event can completely change a company's trajectory.
Eli Lilly's $3.25B acquisition of Colonia is a strategic move to secure future revenue. The company is leveraging massive profits from obesity drugs to buy a potential blockbuster franchise, proactively addressing the eventual patent cliff on its current bestsellers.
Venrock partner Brian Roberts states that a 2-3x return, often considered good in other sectors, is poor in biotech. The decade-long timelines and extremely high failure rates necessitate massive "70x" outlier wins to make a fund's investment model viable.